Form 4: Kewaunee Scientific CEO Sells Shares Under 10b5-1 Plan

Kewaunee Scientific Corp's President and CEO, Thomas David Hull III, sold 884 shares of common stock for a weighted average price of $38.01 per share under a pre-arranged trading plan.

Summary

• Thomas David Hull III, President and CEO of Kewaunee Scientific Corp, reported a sale of common stock.
• The transaction involved the disposition of 884 shares of KEQU common stock.
• The shares were sold on December 29, 2025, at a weighted average price of $38.01 per share.
• The sale was executed pursuant to a Rule 10b5-1 pre-arranged trading plan.
• The shares were sold in multiple transactions at prices ranging from $38.00 to $38.06.
• Following the transaction, Thomas David Hull III beneficially owns 35,835 shares of common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transaction is a routine insider sale under a pre-arranged 10b5-1 plan, involving a small percentage of the executive's holdings, which typically does not carry significant positive or negative implications for the company's prospects.

Positives

• The sale was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on immediate, non-public information, which is a standard practice for executive financial planning.
• The number of shares sold (884) represents a small fraction of the CEO's total beneficial ownership (approximately 2.4% of his holdings prior to the sale), suggesting it is likely for personal liquidity rather than a lack of confidence in the company.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived by the market as a signal, though the small volume in this instance mitigates significant negative interpretation.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction is a routine disclosure and does not inherently provide insight into broader industry trends or competitive landscape. It reflects an individual executive's personal financial planning.

Stakeholder Impact

• Shareholders: The sale is a minor insider transaction and is unlikely to have a significant direct impact on existing shareholders. It provides transparency into executive stock ownership changes.

Key Dates

Keywords

KEQU, Kewaunee Scientific, Insider Transaction, Form 4, Stock Sale, CEO, Director, 10b5-1 Plan